Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Revenue: 2014-2025

Historic Revenue for Zevra Therapeutics (ZVRA) over the last 11 years, with Sep 2025 value amounting to $26.1 million.

  • Zevra Therapeutics' Revenue rose 605.41% to $26.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.4 million, marking a year-over-year increase of 244.63%. This contributed to the annual value of $23.6 million for FY2024, which is 14.02% down from last year.
  • Latest data reveals that Zevra Therapeutics reported Revenue of $26.1 million as of Q3 2025, which was up 0.77% from $25.9 million recorded in Q2 2025.
  • Zevra Therapeutics' Revenue's 5-year high stood at $26.1 million during Q3 2025, with a 5-year trough of $1.3 million in Q2 2022.
  • Moreover, its 3-year median value for Revenue was $8.5 million (2023), whereas its average is $11.2 million.
  • Its Revenue has fluctuated over the past 5 years, first tumbled by 89.15% in 2022, then skyrocketed by 605.41% in 2025.
  • Zevra Therapeutics' Revenue (Quarterly) stood at $2.6 million in 2021, then fell by 21.69% to $2.0 million in 2022, then soared by 538.97% to $12.9 million in 2023, then dropped by 7.03% to $12.0 million in 2024, then spiked by 605.41% to $26.1 million in 2025.
  • Its last three reported values are $26.1 million in Q3 2025, $25.9 million for Q2 2025, and $20.4 million during Q1 2025.